Sibicort

Quick links to important sections

Sibicort

Selected form

Method of action: Anti-Inflammatory, Antipruritic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sibicort

Quick Facts

Property Description
Active ingredient Chlorhexidine Gluconate, Hydrocortisone
Form Topical Cream, Topical Solution
Pharmacological class Topical Antiseptic and Corticosteroid Combination
Common purpose To relieve inflammation and protect against surface bacteria
Origin Synthetic

Understanding Sibicort: A Combination Topical Agent

Sibicort is accurately defined as a fixed-dose combination product intended for topical administration to the skin, classified as a dual-acting medicine containing both an antiseptic and a corticosteroid. This preparation is a specialized pharmaceutical product, not a single drug, which delivers two distinct, complementary pharmacological actions simultaneously in one application. It is supplied in common topical dosage forms, such as a cream or a solution. The utility of this specific pairing—a corticosteroid and an antiseptic—is clinically recognized for providing relief in situations where skin inflammation and the risk of surface microbial activity coexist. Sibicort represents one of several commercially available fixed-dose products utilizing this well-established dual-component formulation.

Composition and Pharmacological Identity of Sibicort

Sibicort’s composition includes the two active ingredients: Hydrocortisone and Chlorhexidine Gluconate, which together define its unique pharmacological identity. Hydrocortisone is a mild glucocorticoid and a type of topical corticosteroid, a synthetically derived steroid hormone used to modulate the body’s inflammatory response. The second agent, Chlorhexidine Gluconate, is a potent antimicrobial agent and antiseptic belonging to the bisbiguanide chemical family. Both compounds are of synthetic origin. This combination provides a targeted therapeutic profile, differentiating it from formulations that contain only a steroid or only an antimicrobial.

The General Purpose of Sibicort’s Dual Action

The general purpose of Sibicort's dual action is to simultaneously calm inflammation and protect the compromised skin surface from potential bacterial colonization. The Hydrocortisone component is specifically included to help alleviate the key uncomfortable symptoms of skin irritation, such as intense swelling, redness, and itching (pruritus). Concurrently, the Chlorhexidine Gluconate component exerts its antimicrobial activity right on the skin's surface, helping to maintain a cleaner environment. A typical scenario for its use involves localized skin flare-ups where there is a need for both symptomatic relief and hygienic protection. This two-pronged approach focuses solely on providing localized symptom relief and surface protection.

What side effects are possible with Sibicort?

Possible Side Effects and Safety Information

The official safety profile for topical Hydrocortisone/Chlorhexidine combinations is structured around risks associated with its two active components, as defined in government regulatory documents.


Adverse Reaction Scope

Category Regulatory Statement
Key Adverse Reaction Categories Local skin reactions (corticosteroid effects) and generalized hypersensitivity risks (antiseptic effects).
Frequency Classification Rare: Serious systemic hypersensitivity, including anaphylaxis and anaphylactic shock. Frequency Not Known/Common: Local effects such as burning, pruritus (itching), irritation, and dryness.
System-Organ Classes Involved Skin and Subcutaneous Tissue Disorders (e.g., atrophy, striae); Endocrine Disorders (e.g., adrenal suppression); Immune System Disorders.
Serious Adverse Reactions Anaphylactic Shock (Chlorhexidine) and HPA Axis Suppression leading to potential adrenal insufficiency (Hydrocortisone).
Population-Specific Safety Pediatric Population: Higher risk of systemic toxicity (HPA axis suppression); long-term continuous use in infants is generally advised against.
Exposure-Related Patterns Prolonged Use: Associated with increased risk of local effects (skin atrophy) and systemic effects. Cessation: Risk of Topical Steroid Withdrawal (TSW) reaction or rebound flare following cessation after prolonged use.
Safety Restrictions Avoidance: Must avoid contact with the eyes, mucous membranes, and middle ear. Application: Risk of systemic absorption is increased with extensive application or use under occlusive dressings.

Connection to the Overall Safety Profile

The regulatory framework defines the risk profile by categorizing adverse effects based on the specific active ingredient and the mode of exposure, clearly separating common local effects from rare, systemic safety concerns. This profile explicitly links the potential for serious adverse reactions, such as adrenal suppression and severe allergic events, to factors of time, surface area, and patient age.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information addresses two primary areas of overdose risk for this combination product (Hydrocortisone and Chlorhexidine Gluconate).


Documented Overdose Manifestations

Component Risk Profile and Manifestations
Hydrocortisone Systemic corticosteroid excess from prolonged or excessive topical use may result in HPA-axis suppression and features of Cushing’s syndrome. Management involves the gradual withdrawal of the medication and periodic evaluation for suppression.
Chlorhexidine Gluconate Acute systemic toxicity is associated with unintentional ingestion, potentially leading to gastric irritation and changes in consciousness. A rare but severe risk is a life-threatening allergic reaction (anaphylaxis) from any route of exposure.

Emergency Actions Mandated by Regulators

Immediate medical attention is required for any signs of a serious allergic reaction, such as difficulty breathing, severe rash, or swelling of the face or throat. Regulatory documents explicitly state to seek medical attention immediately or call emergency services if these symptoms occur. In cases of accidental ingestion, contact with a poison control center or obtaining medical help immediately is mandated. Pediatric patients are officially noted as being more susceptible to systemic toxicity from topical over-absorption, requiring careful monitoring for signs like linear growth retardation.

Therapeutic Uses of Sibicort

This product is applied across domains where additional symptomatic support is needed in conditions involving inflammatory or irritative processes that are also associated with microbial manifestations.

The medication is commonly used across conditions characterized by periods of heightened symptoms of dermatoses where fungal and/or bacterial factors are present. The product is relevant for easing symptoms that become more disruptive during flare-ups of conditions like eczema, intertrigo, and nappy rash where microbial factors are involved.

The application of this product may assist with managing symptom clusters related to redness, swelling, and itching that interfere with daily comfort. This is used for managing symptom clusters that may become intense or disruptive. The formulation supports patients during difficult episodes by easing distress and is considered relevant when supportive relief is needed. This assistance contributes to easing the overall symptom load during episodes of heightened discomfort.


Quick Fact: Support for Acute Symptom Manifestations

Property Therapeutic Focus
Symptom Cluster Redness, swelling, intense itching
Condition Category Conditions involving inflammatory or irritative processes (e.g., eczema, intertrigo)
Patient Benefit Supports patients by easing distress
Context of Use Applied when symptoms are associated with acute or episodic changes

Regulatory References

  1. Summary of Product Characteristics (SmPC) for Nystaform HC Cream

Eligibility and Restrictions for Use

Who Can and Cannot Use Sibicort?

Sibicort is contraindicated for individuals with known hypersensitivity to Hydrocortisone, Chlorhexidine, or any ingredient in the formulation. The product must not be used in the presence of primary skin infections, including viral diseases like Herpes Simplex and Varicella, as well as fungal infections or Tuberculous lesions of the skin. Specific skin pathologies, such as Rosacea, Acne vulgaris, and Perioral dermatitis, are also absolute contraindications.

Population and Use Restrictions

Use is not recommended in children under two years of age. In all pediatric patients, long-term continuous topical therapy must be avoided to mitigate the risk of systemic absorption. Application is contraindicated under occlusive dressings, including tight-fitting infant nappies, and must not be applied to the eyes or the external ear canal if the eardrum is perforated.

For pregnant individuals, use is generally not recommended for extensive areas or prolonged periods. Individuals who are breastfeeding must not apply the product to the breasts or nipples.

What should I know about interactions with other medicines?

The official regulatory profile for Sibicort addresses documented interactions based on the potential for systemic absorption of the hydrocortisone component and a local substance interaction involving chlorhexidine gluconate. As a topical product, drug-drug interactions are conditional, relying upon the systemic exposure of hydrocortisone, which is typically augmented by application over large surface areas, prolonged use, or under occlusive dressings.


Official Interaction Statements

  • Pharmacodynamic Risk with Potassium-Depleting Agents: Co-administration with specific diuretics or similar agents may increase the need for close observation regarding the potential development of hypokalemia (low potassium levels). This pharmacodynamic interaction is contingent on significant systemic hydrocortisone exposure.
  • Exposure Modification: Aminoglutethimide may lead to a loss of the corticosteroid-induced adrenal suppression effect. This effect is conditional on systemic absorption reaching a level that causes adrenal suppression.
  • Population-Specific Note: Official documentation indicates an enhanced effect of corticosteroids in patients with cirrhosis, which potentially heightens the risk of conditional systemic interactions.
  • Substance Restriction: The chlorhexidine gluconate component will cause permanent stains on fabrics if they are laundered with chlorine-releasing products, such as household bleach.

Mechanism of Action

Sibicort is a combination product containing Hydrocortisone acetate and Dequalinium chloride.

Hydrocortisone acetate, a glucocorticoid, acts as an agonist for the intracellular glucocorticoid receptor (GR). Upon ligand binding, the activated GR translocates to the nucleus, where it functions as a transcription factor. This complex binds to glucocorticoid response elements (GREs) to initiate the transactivation of specific target genes, increasing the synthesis of anti-inflammatory proteins like Annexin A1 (Lipocortin-1). Concurrently, the GR complex engages in transrepression, physically inhibiting the activity of pro-inflammatory transcription factors, such as NF-kappaB and AP-1, thereby preventing the transcription of genes encoding inflammatory mediators (e.g., cytokines, chemokines, and adhesion molecules). This process results in a broad systemic modulation of the inflammatory cascade by decreasing the presence of signaling molecules required for cellular recruitment and activity.

Dequalinium chloride, a quaternary ammonium compound, exhibits localized activity through multiple mechanisms. It is a membrane-active agent that targets microbial cells. Its positively charged cation interacts with the negatively charged components of the bacterial cell wall and membrane, leading to the disruption of cell membrane integrity and increased permeability. This action causes the leakage of essential intracellular components. Furthermore, dequalinium chloride is mitochondriotropic, accumulating in microbial mitochondria where it inhibits mitochondrial ATP synthesis and other metabolic processes, effectively depleting cellular energy and inducing cell death. It also demonstrates DNA-binding capability, where it can intercalate into nucleic acids to interfere with replication and transcription.

Dosage and Administration Information

How to Use Sibicort: Official Administration Guidelines

Sibicort, a fixed-dose combination of hydrocortisone and chlorhexidine, is intended strictly for topical administration to the skin. The guidelines for its use are structured around principles that ensure localized application and strictly limited exposure time. The official schedule involves applying the preparation as a thin film to the affected area, typically two to four times daily.


Administration Scope and Dosing Constraints

The usage protocol emphasizes a limited treatment duration. The medicine is designated for short-term use and should generally not be prolonged beyond a period such as seven days. If an application is missed, it should be applied as soon as the omission is noticed, unless it is close to the time of the next scheduled application, in which case the missed dose is skipped.

Instruction Detail
Route of administration Topical (External use only)
Frequency and timing Applied two to four times daily
Special procedural condition Do not cover with an occlusive dressing unless directed by a physician.

Population-Specific Rules

Specific limitations exist for pediatric patients. Administration to children requires using the least amount necessary for the shortest duration compatible with the required frequency. When applied to the diaper area of an infant, tight-fitting diapers or plastic pants must be avoided, as these function as occlusive dressings. The preparation must also be kept away from the eyes and mucous membranes.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sibicort

Evidence for Use in Dermatoses with Microbial Manifestations

Research was studied for this combination topical agent applied in research contexts involving fluctuating or unstable symptoms where inflammation and the presence of surface bacteria may be factors, such as specific cases of eczema (dermatoses) and intertrigo. These investigations are typically short-term, randomized controlled trials (RCTs). The studies were applied in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort, such as observer-assessed overall skin lesion severity and patient-reported levels of discomfort including redness, swelling, and itching.

The research also examined the relationship between the medicine and changes in the surface microbial load on the skin of participants. The studies were conducted during periods of increased symptom activity and included patient groups consisting of adults and specific subsets of pediatric patients. Research highlights changes measured during the study period; findings describe patterns observed in the studies related to how symptoms changed in the observed populations over these defined time intervals. These studies contribute to the broader evidence landscape by exploring short-term symptom changes, but research does not determine whether an individual will respond similarly to the group patterns reported.

However, the evidence base for the steroid component (Hydrocortisone) is extensive. This research contributes to understanding symptom patterns in inflammatory skin conditions. For the combination product specifically, the evidence is often drawn from a limited number of dedicated RCTs that focused on demonstrating equivalence to the steroid alone. Subgroup findings are uncertain regarding whether the combination was associated with a difference when compared to the corticosteroid alone in all contexts studied.


Long-Term Studies and Follow-Up Data

Available evidence for the combination product is heavily concentrated on research exploring short-term symptom changes and acute flare-ups. The follow-up durations in the dedicated combination trials were limited, typically to two to four weeks.

Consequently, long-term effects are not fully established for this specific combination product. There is limited information for long-term outcomes regarding the effects of using the product over extended periods or for maintenance. The durability of any observed response is an area where data are still emerging, and sustained use was not the primary focus of the initial clinical evaluations. The available evidence, therefore, provides context but not individual predictions regarding sustained effects.


Key Limitations and Areas of Research Uncertainty

One primary limitation is the number and size of the dedicated studies: sample sizes were modest, and comparative evidence is lacking for certain important clinical comparisons. Furthermore, because the trials focused on acute episodes, follow-up durations were limited. Finally, because skin conditions are diverse and the microbial component can vary widely, evidence quality varies across studies, leading to findings were mixed in some instances. The research evidence highlights what is known and what is still uncertain regarding this combination.

Key Studies & References Hydrocortisone Topical Monograph

Frequently Asked Questions (FAQ)

Common questions about Sibicort (FAQ)


Q: Is Sibicort considered a 'strong' or potent medicine compared to similar drugs?

A: According to regulatory documents, Sibicort contains hydrocortisone, which is generally classified as a mild or low-potency topical corticosteroid. This classification helps define its intended use and systemic risk profile compared to other prescription steroid medicines.

Q: Can Sibicort be used to help reduce common pain?

A: Official product information indicates that the corticosteroid component is intended to help alleviate inflammatory symptoms like swelling and itching, but pain relief is not listed as a primary, specific indication of the medicine.

Q: Is hair loss a documented or commonly reported side effect of Sibicort?

A: Official safety documents for the corticosteroid component describe excessive hair growth (hypertrichosis) as a potential adverse reaction. In very rare cases linked to significant systemic absorption, hair loss has also been noted as a potential systemic effect.

Q: Is there information on whether Sibicort causes weight gain or appetite changes?

A: Regulatory information notes that if the corticosteroid component is absorbed systemically in high amounts—which is rare with proper use—it may rarely lead to certain effects, such as manifestations including weight gain, associated with systemic corticosteroid absorption.

Q: Can Sibicort potentially affect a person's mood, anxiety, or sleep patterns?

A: Significant systemic absorption of the corticosteroid component can rarely cause central nervous system (CNS) effects. Official safety profiles for systemic steroids may list potential changes to mood, anxiety, or sleep patterns. These effects are typically observed with systemic corticosteroid use and are considered highly unlikely when the low-potency topical product is used according to directions.

Q: What are the known effects of Sibicort on major organs like the liver or kidneys?

A: The active hydrocortisone component, if absorbed into the bloodstream, is primarily broken down (metabolized) by the liver and removed by the kidneys. While absorption is usually minimal, the regulatory profile indicates that caution should be exercised for individuals with known pre-existing liver or kidney conditions.

Q: Is there any known risk of becoming physically dependent on Sibicort?

A: Official documents state that continuous, prolonged use of topical steroids can carry a risk of developing a Topical Steroid Withdrawal (TSW) reaction or dependence. This condition is documented in official sources and may involve a rebound flare of symptoms or adverse reactions following cessation. The product is therefore designated for short-term use.

Q: What are the signs or symptoms of a rare, severe allergic reaction to Sibicort?

A: A rare, severe allergic reaction called anaphylaxis is associated with the chlorhexidine component of the medicine. Signs of this serious event, as listed in regulatory warnings, can include hives, swelling of the face or throat, difficulty breathing, or a sudden drop in blood pressure.

Q: Does Sibicort have any impact on blood pressure or blood sugar levels?

A: If the hydrocortisone is absorbed systemically, it may rarely cause hyperglycemia (elevated blood sugar) and hypertension (high blood pressure). Official regulatory documents indicate that special caution and monitoring may be necessary for individuals with pre-existing conditions like diabetes or high blood pressure.

Q: Is Sibicort generally considered safe for use during pregnancy or while trying to conceive?

A: Official guidance states that use during pregnancy is generally not recommended over large skin areas or for prolonged periods of time. Available evidence is limited, and the safety of the medicine when actively trying to conceive is not detailed in regulatory documents.

Q: Can individuals over 65 years old safely use Sibicort?

A: Regulatory guidance suggests that no specific dose adjustment is generally required for the elderly population. However, official guidance notes that attention to the potential for systemic absorption is warranted in this population due to factors like age-related skin changes or pre-existing conditions.

Q: Can I use Sibicort if I have a pre-existing health condition like high blood pressure or diabetes?

A: Because there is a possibility of some systemic absorption, the regulatory profile indicates that special caution may be necessary for individuals with certain pre-existing systemic conditions. This includes high blood pressure and diabetes, as the hydrocortisone component can affect blood sugar and blood pressure levels.

Q: Is Sibicort safe for use in patients who have a weakened immune system?

A: Official regulatory information describes how corticosteroids can affect the body’s immune response. Due to this, the medicine may be associated with a potential for reduced resistance to new infections or the exacerbation of existing ones. For this reason, the medicine is strictly contraindicated for use on skin with primary infections.

Q: Can I apply other moisturizing creams or topical products alongside Sibicort?

A: Official regulatory labeling focuses on warnings against the use of occlusive dressings (such as plastic wrap or certain bandages), as these can increase systemic absorption of the active ingredients. While other topical products are not explicitly restricted, the general guidance from regulatory sources emphasizes avoiding any practice that could lead to increased absorption.

Q: Why do official documents assign Sibicort a specific risk warning or boxed warning?

A: Official safety documentation highlights serious potential risks associated with the two active ingredients, which necessitates prominent warning statements. These risks include the potential for HPA axis suppression from the steroid and the rare risk of anaphylaxis from the chlorhexidine component.

Q: How does Sibicort differ from a typical over-the-counter anti-itch or anti-inflammatory medicine?

A: Sibicort is defined as a fixed-dose combination product that provides dual action: it contains both a corticosteroid (hydrocortisone) to manage inflammation and an antiseptic (chlorhexidine gluconate) to address surface microbial activity. Many typical over-the-counter products contain only one such active component.

Q: Does Sibicort contain any ingredients that commonly trigger sensitivities or allergies?

A: The official product information specifies that the medicine is strictly contraindicated for anyone with a known hypersensitivity to any of its ingredients, including both active and non-active components. Non-active ingredients like preservatives, emulsifiers, or alcohols commonly found in topical products can sometimes trigger sensitivities in individuals.

Q: What are the non-active ingredients in Sibicort and what is their purpose?

A: The complete list of non-active ingredients (also called excipients) is fully detailed in the official product labeling. These components are included to serve roles such as forming the cream or solution base, ensuring the stability of the medicine, and aiding in the application of the active ingredients to the skin.

Q: Can Sibicort be used on delicate or sensitive skin areas, such as the face?

A: Regulatory guidance strictly warns against application to the eyes, mucous membranes, or the external ear canal. Regulatory guidance indicates that special attention should be given to use on delicate areas like the face, armpits, or groin. The skin in these areas is thinner and may carry a higher risk for developing side effects like skin thinning (atrophy).

Q: What is the most common reason listed in official contraindications for someone to avoid using Sibicort?

A: Official regulatory information lists multiple absolute contraindications for use. These include known hypersensitivity to any ingredient and the presence of underlying skin pathologies, especially primary skin infections such as viral diseases (like herpes) and fungal infections.

Q: Is Sibicort absorbed into the bloodstream, and if so, how much?

A: Official documents state that the active components can be absorbed into the bloodstream from the skin. The extent of this systemic absorption is variable and increases with prolonged use, application over large body surface areas, or when the product is covered with an occlusive dressing. The absorption level is not defined as a fixed quantity.

Q: What is the half-life of Sibicort in the body?

A: Because the medicine is intended for localized action, the biological half-life is mainly relevant when the steroid component is absorbed systemically. The systemic half-life of absorbed hydrocortisone is approximately 8 to 12 hours. The half-life for the antiseptic component is not generally provided in topical drug specifications.

How should Sibicort be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal of Sibicort, a topical combination product, must strictly follow the requirements set forth in government regulatory labeling to maintain product stability and ensure public safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, typically between 15 C and 30 C (59 F and 86 F). Do not freeze.
Protection Keep in the original container, tightly closed, and protect the product from excess heat and direct light.
Child Safety The medicine must be stored out of the sight and reach of children.

Disposal Rules

Requirement Official Instruction
Discarding Dispose of unused or expired medicine according to local requirements for pharmaceutical waste.
Restrictions The product must not be emptied into drains or disposed of with general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sibicort found in:

A-Z Index: